|AHFS/Drugs.com||International Drug Names|
|Metabolism||N-desmethylation to norzotepine (30-40%)|
|Elimination half-life||13.7–15.9 hours, 12 hours (Norzotepine)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||331.86 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Zotepine is not approved for use in the United States, United Kingdom, Australia, Canada or New Zealand.
Zotepine's primary use is as a treatment for schizophrenia although clinical trials have been conducted (with positive results) into its efficacy as an antimanic agent in patients with acute bipolar mania. In a 2013 study in a comparison of 15 antipsychotic drugs in effectivity in treating schizophrenic symptoms, zotepine demonstrated medium-strong effectivity. Less effective than clozapine, slightly less effective than olanzapine and risperidone, approximately as effective as paliperidone, and slightly more effective than haloperidol, quetiapine, and aripiprazole.
The antipsychotic effect of zotepine is thought to be mediated through antagonist activity at dopamine and serotonin receptors. Zotepine has a high affinity for the D1 and D2 receptors. It also affects the 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors. In addition, its active metabolite, norzotepine, serves as a potent norepinephrine reuptake inhibitor.
|Macromolecule (Receptor or transporter protein)||Ki [nM]|